<DOC>
	<DOCNO>NCT00909298</DOCNO>
	<brief_summary>The purpose study determine post-operative administration intrinsic pathway antagonist ( TTP889 ) patient Left Ventricular Assist Device ( LVAD ) support result 50 % reduction thrombin generation marker 28 day compare placebo .</brief_summary>
	<brief_title>Left Ventricular Assist Device ( LVAD ) Specialized Centers Clinically Orientated Research ( SCCOR ) Coagulation - Acute Intrinsic Pathway Antagonist ( IPA )</brief_title>
	<detailed_description />
	<criteria>Signed informed consent , release medical information , HIPAA form Age great equal 18 year Male , postmenopausal female , female may become pregnant use adequate contraceptive precaution ( defined oral contraceptive , intrauterine device , surgical contraception combination condom spermicide ) , negative pregnancy test Implanted FDAapproved LVAD ( BTT DT indication , e.g . HeartMate® XVE ) within 72 hour prior randomization , able receive first dose study drug 72 hour ( +6 hour ) post LVAD implantation Postop hemostasis adequate start low level anticoagulation ( assessed surgeon ) Extubated able take oral medication Evidence active bleeding within 24 hour prior randomization History platelet disorder , include limited thrombocytopenia thrombasthenia Thrombocytopenia platelets &lt; 80,000/ml within 48 hour prior randomization History inherit acquire coagulation disorder Hemoglobin &lt; 8 g/dL ( 4.85 mmol/L ) hematocrit &lt; 26 % within 24 hour prior randomization Clinical indication ( intention use ) standard anticoagulation therapy time randomization ( e.g. , atrial fibrillation DVT ) Intention treat 325 mg aspirin daily Any clinical requirement intention treat phenytoin , tolbutamide warfarin post randomization RVAD support time randomization Estimated glomerular filtration rate ( GFR ) ≤30 ml/min ( CockcroftGault formula ) , form dialysis within 48 hour prior randomization Evidence intrinsic hepatic disease define biopsy proven liver cirrhosis ; liver enzyme value ( AST ALT ) &gt; 3 time upper limit normal ; Total Bilirubin &gt; 1.5 time upper limit normal ( exception Gilbert 's Syndrome ) within 3 day prior randomization Active systemic infection , judgment investigator , within 3 day prior randomization Stroke transient ischemic attack ( TIA ) within 6 month prior randomization History intracranial hemorrhage gastrointestinal bleed within 3 month prior randomization Alzheimer 's disease , form irreversible dementia History psychiatric disease ( include drug alcohol abuse ) may impair compliance study protocol Pregnant breastfeeding time randomization Received investigational intervention within 30 day prior randomization Body weight &lt; 45 Kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Left ventricular assist device</keyword>
	<keyword>Cardiac Disease</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Anticoagulant Left Ventricular Assist Devices</keyword>
</DOC>